SUMMARY
INTRODUCTION
Hepatitis C virus is a human pathogen causing chronic liver disease in 170 million people worldwide. The virus is classified within the family Flaviviridae (1) . The RNA genome is singlestranded and functions as the sole mRNA species for translation (1) (Fig. 1A ). It comprises a 5'-untranslated region, which functions as an internal ribosome entry site (2) , and a long open reading frame, which encodes a polyprotein precursor of about 3010 amino acids, that is cleaved into structural (core, envelope 1, envelope 2 and p7) and non-structural (NS-2, NS-3, NS-4 and NS-5) proteins (3); followed by a 3' non-coding region (4) .
Analyzing significant numbers of cDNA clones of hepatitis C virus (HCV) from single isolates provides unquestionable proof that the viral genome cannot be defined by a single sequence, but rather by a population of variant sequences closely related to one another (5-7). In the infected patient, a master (the most frequently represented sequence) and a spectrum of mutant sequences (diverging by up to 5%) may be isolated at any given time during chronic infection (7) .
This manner of organizing genetic information, which characterizes most RNA viruses, is referred to as quasispecies (8) . It has been proven that the use of this strategy provides RNA viruses with a rapid increase of fitness while growing in cell culture conditions (9) .
Many studies on genetic variability in recent years have focused on the analysis of HCV quasispecies. Clinically relevant features, such as the ability to produce chronic infections and severity of disease (including the frequency of hepatocellular carcinoma), have been related to the interplay between host influences and the array of viral variants in each infected individual (10) .
HCV resistance to interferon treatment (either alone or in combination with ribavirin) is one of the most important clinical implications predicted by the quasispecies model (11) (12) (13) (14) suggesting the necessity to seek new therapies. HCV therapeutic strategies based on ribozyme cleavage are leading candidates. It may be argued that a sequence-dependent ribozyme designed to cleave viral RNA by interaction with a motif in the viral RNA, may, in fact select for (mismatching) variants resistant to the ribozyme. However, strategies could be designed to take advantage of ribozyme capabilities to minimize the effect of virus variability. Combination therapy with multiple ribozymes directed against independent viral loci has been demonstrated to be efficient in inhibiting influenza virus replication in cell culture (15) . Making conserved motifs within the viral genome accessible to therapy, as in the case of the HCV IRES, could be another promising strategy.
The ribozyme activity of Ribonuclease P (RNase P) is among proposed antiviral agents (16) .
RNase P is a ubiquitous cellular endonuclease and one of the most abundant and efficient enzymes in the cell. This enzyme is a ribonucleoprotein complex that catalyzes a hydrolysis reaction to remove the leader sequence of precursor tRNA to generate the mature tRNA (17) . RNase P from Escherichia coli contains a catalytic RNA subunit termed M1 RNA and a single polypeptide known as C5 protein (18) . In the presence of a high concentration of Mg 2+ , M1 RNA itself can hydrolyze tRNA precursors in vitro (19) . Human RNase P also contains an RNA subunit, H1 RNA, but in the absence of protein factors, H1 RNA does not exhibit enzymatic activity by itself in vitro (20, 21) . Substrate recognition by the RNase P ribozyme does not rely on sequence requirements but on structural features of the RNA substrate. Custom-designed ribooligonucleotides, which hybridize with the target, called external guide sequences (EGSs), may provide the RNA structure which RNase P recognizes and cleaves in the hybridized complex (16) .
Recognition of structures instead of sequences may represent a great advantage in the fight against variable viruses because single or even double mutations in the target may be tolerated for RNase P recognition (15) . Also, it has already been shown that some forms of the catalytic RNA moiety from E.coli RNase P, M1 RNA (either specifically modified or in vitro selected) can be introduced into the cytoplasm of mammalian cells for the purpose of carrying out targeted cleavage of mRNA molecules (22, 23) .
While performing targeting experiments on HCV RNA transcripts with RNase P we have found that, surprisingly, purified RNase P (peak activity) from HeLa cells cleaved HCV genomic RNA efficiently at two sites in the absence of EGSs. We report here the techniques used to prove that the cleavage is specific to human RNase P, and to show where cleavage occurs. We further report that cleavage is maintained in several variant sequences, which makes RNase P cleavage an inherent property of HCV RNA. Since RNase P recognizes and cleaves tRNA-like structures, these results suggest the presence of tRNA like structures within the viral genome.
EXPERIMENTAL PROCEDURES Preparation of RNA transcripts
RNA transcripts used as substrates in the human RNase P assays derived from plasmids pN(1-4728) Bluescript, which contains nt 1-4728 of hepatitis C virus under the T7 promoter, and pUC19 TyrT which contains the sequence of the naturally occurring precursor to tRNA Tyr . To obtain the radioactive substrates for peak RNase P activity from HeLa cells, one to two µg DNA template were transcribed in vitro (1 h at 37ºC) with [α-32 P]-GTP or [α-32 P]-NTPs followed by a 5 min treatment with RNase-free DNase I at 37ºC. We used cellulose CF11 chromatography to eliminate DNA fragments and non-incorporated nucleotides. Transcripts were then purified by gel electrophoresis under denaturing conditions on 4% polyacrylamide gels containing 7M urea. Bands were visualized by autoradiography, excised from the gel and eluted in buffer (100mM Tris-HCl, pH 7.5 and 10mM EDTA, pH 7.5). The concentration of Fractions with coincident peaks of enzymatic activity and H1 RNA amplification were pooled and concentrated using the Millipore Ultrafree-15 Centrifugal Filter Device, to a final volume of approximately 6 ml. The concentrated fractions were subjected to linear glycerol gradient centrifugation, as described (20) . Relative quantitation of RNase P and MRP RNA molecules at this point confirmed previous results, that is enrichment of RNase P versus MRP during the purification process (6.7 x 10 10 molecules of RNase P RNA versus 6.7 x 10 7 molecules of MRP RNA, on average, in the fractions from the glycerol gradient). Again, fractions containing the peak of enzymatic activity were concentrated to a final volume of 0.1ml and stored at -70ºC.
RNase P cleavage assay
Substrates for RNase P assays, S I , S II, S III and S IV transcripts (1.8 nM final concentration), were preheated at 90ºC for 1 min, before the addition of reaction buffer (10mM HEPES-KOH, pH 7.5, 10mM MgOAc, 100mM NH 4 OAc) and left to cool to room temperature.
Cleavage reactions were performed with 4% PEG, 20U RNasin and 2 µl of the RNase P peak activity, and carried out at 30ºC in a volume of 10 µl for 30 min. Samples were subjected to 2% SDS and 5 min at 60ºC to disrupt aggregates before loading. Cleavage products were separated on 4% denaturing polyacrylamide gels and visualized by autoradiography.
Determination of cleavage site and phosphate polarity
Oligonucleotides released from RNase T1 digestions of all four single or mixed labeled S I , 5'P I and 3'P I RNAs, were fractionated to yield two-dimensional fingerprints (first separation by gel electrophoresis and second by homochromatography) exactly as described (25) . Standard conditions for secondary analysis (with pancreatic RNase A, RNase U2, RNase T2 or 0.4 M NaOH) (26) were followed permitting the oligonucleotides to be identified. One-dimensional electrophoresis on DEAE or 3MM paper was done following Barrells' protocol (26) .
Immunoprecipitation of RNase P activity
Serum containing anti-Th antibodies from a patient with an autoimmune disease was used to immunodeplete RNase P activity (27) . Protein A Sepharose (PAS) beads (125µg of dry weight, Pharmacia) were washed with TMKT buffer (10mM Tris-HCl, pH 7.5, 10mM MgCl 2 , 100mM KCl, 0.02% Tween 20) before incubation for 1 h at room temperature at different concentrations of either normal serum or anti-Th serum (0.25, 0.5 or 1 µl) and in 30 µl of TMKT buffer. After washing four times in TMKT, followed by three washes in RNase P Buffer (10mM HEPES-KOH, pH 7.5, 10mM MgOAc, 100mM NH 4 OAc), the beads were incubated for 2 h at 4°C in 2.5 µl of RNase P extract. The suspension was centrifuged, and both the supernatant and the immunoprecipitate were assayed for enzyme activity. To facilitate migration of products on the acrylamide gel, an additional step of proteinase K treatment was carried out after phenol/SDS treatment, on each reaction tube.
Construction of plasmids containing HCV variants
HCV variants were obtained from our library of cloned fragments encompassing HCV nucleotides 2641-2872 from infected patients. Subsequently the fragments were extended by PCR at their 3' ends using primers HCV-2639:
5'ACAGGATCCAGTCCTTCCTTGTGTTCTTCT3' and HCV-2871:
5'AACGAATTCCCACACATGCAAGTGCGCCTCAGCTCTGGTGATAAGATATTGTAACC ACCA3', corresponding to the "wild type" clone (this length of 3' extension was required for cleavage (data not shown)). Amplified DNA fragments were inserted in BamHI/EcoRI sites of pGem-4Z. RNAs were synthesized from EcoRI linearized plasmids and contained an additional 45 nt stretch of plasmid polylinker. S I transcript, the DNA template for which has been cloned in the same manner as the variant sequences, was referred as to wild type in these experiments.
Nucleotide sequence accession numbers
The nucleotide sequence for the HCV wild type genome is available in the GenBank database under GenBank Accession Number S62220 (28) .The nucleotide sequence for HCV variants presented in this article can be accessed through EMBL database under EMBL database accession number AJ248084, AJ391467, AJ391452 and AJ247989 (7) .
RESULTS

Cleavage of HCV RNA transcripts
Initial RNase P cleavage experiments involved a 554-base HCV RNA transcript (S I nt 2486-3040). At the top of figure 1A is a schematic drawing of the HCV RNA genome, below which appears the S I transcript located at the structural/non-structural junction region. The autoradiogram in figure 1B shows that, using the S I transcript as a substrate, RNase P peak activity alone, in the absence of any EGS, cleaved the HCV transcript very efficiently, producing two intense cleavage products (5'P I and 3'P I ). After this unexpected result we wanted to assess if cleavage was maintained in a larger transcript, encompassing the first one third of the genome (Fig.1A , S II nt 1-3032). In the course of that demonstration, we detected a second HCV cleavage site in the IRES region ( Fig. 1A and 1C) . Subsequently, cleavage within the IRES was confirmed using a third transcript corresponding to the first 1360 bases of HCV genome (Fig. 1A , S III nt 1-1360) as well as in a shorter fragment, 641 nt long (S IV nt 1-641).
RNase P is responsible for the HCV RNA cleavages
The key experimental question of the HCV RNA cleavages obtained in the reactions involving non-guided RNase P concerns demonstration that cleavages in different sized transcripts are performed by RNase P itself, and not by a co-extracted contaminant. To prove that, we have used direct and indirect methods.
Direct Method: End group determination and cleavage precision by RNA fingerprinting .
If RNase P were responsible for HCV RNA processing activity in our RNase P peak activity (HeLa cell extract), the site of cleavage might be expected to occur between precise nucleotide positions, and release products containing the 3' hydroxyl and 5' phosphate end groups (17) . Contaminating RNases almost invariably cleave to yield 5' hydroxyl and 3' phosphate end groups (29) , and very few other RNases and ribozymes cleave the phosphodiester backbone through the same mechanism used by RNase P (30) . S I RNA substrate: To allow direct and precise determination of the cleavage site as well as to identify the phosphate polarity of the newly cleaved termini, substrate S I was internally labeled either separately with [α-32 P] -GTP, -ATP, -CTP and -UTP, or simultaneously with all four-labeled rNTPs and incubated with RNase P peak activity under the conditions described in the experimental procedures. Both cleavage products (5'P I and 3'P I ) and control transcript (S I ) were fractionated by gel electrophoresis, eluted from the gel and subjected to RNase T1 digestion. Figure 2 shows two-dimensional fingerprint analysis (25) of the oligonucleotides generated by RNase T1 digestion of single or mixed labeled uncut S I substrate, 5'P I and 3'P I cleavage products, and identifies the exact phosphodiester bond cleaved during the cleavage reaction to be between residues A2860 and G2861 within the four base RNase T1-resistant oligonucleotide 2858 CUAG 2861 found to be missing from both the 5' P I and 3' P I fingerprint patterns (data confirmed by secondary RNase digestion, not shown). These experiments also demonstrate that the final position of the phosphate group is 5' to the cleavage. More precisely, the arrow in panel D indicates that a new spot appears in the GTP-labeled 3' P I fingerprint that does not appear in the UTP-labeled 3' P I
(arrow in panel C). Neither does it appear in panels A and B nor in the ATP-nor CTP-labeled 3' P I fingerprints (data not shown). This novel spot was eluted and confirmed to be the 5' terminal residue pGp, by its mobility with respect to markers in secondary analysis by one-dimensional electrophoresis on DEAE and 3MM paper (26) .
S IV RNA substrate: Figure 3 depicts RNA fingerprinting analysis of the substrate S IV RNA, corresponding to the HCV IRES, as well as both cleavage products generated by RNase P.
In each case, T1-resistant oligonucleotides were eluted and subjected to further enzymatic characterisation as described elsewhere (26) . 
Indirect methods: Immunoprecipitation and competitive inhibition
Two indirect strategies were used to demonstrate that the activity which cleaves S I and S II , and which exactly co-purified with RNase P peak activity, was in fact RNase P. The experiments were carried out using S I , S II and S III as substrates.
Immunoprecipitation: Some patients with autoimmune diseases produce antibodies against a 38-40 kDa protein (designated Th antigen) which is an integral component of eukaryotic RNase P (27) . In the immunoprecipitation experiment we have incubated a serum containing anti-Th antibodies with our peak activity (RNase P extract) and we have assayed both the supernatant and the pellet. The anti-Th serum that immunodepleted pre-tRNA Tyr cleavage activity from our glycerol gradient-purified enzyme (Fig. 4A, lane 2 ) also immunodepleted cleavage of HCV transcripts (Fig. 4B, lanes 6-8; Fig. 4C, lanes 22-24) . Moreover, the autoimmune serum was able to precipitate the processing activity of HCV transcripts S I and S II (Fig. 4B, lanes 9-11; Fig. 4C , lanes 25-27) as well as pre-tRNA Tyr (Fig. 4A, lane 3) and a human suppressor pre-tRNA (data not shown). In contrast, the normal human serum failed to precipitate the processing activity ( Fig. 5A, lane 5) . With the long transcript (S II ), a decrease of products from the two cleavage reactions was more noticeable when the molar ratio between pre-tRNA Tyr and S II reached 2:1 (Fig. 5B) .
RNase P cleaves HCV variants
The direct consequence of the high mutation rate in HCV replication is that variant genomes are continuously being generated. Thus, multiple variant sequences (quasispecies) cocirculate within a patient and each patient carries a virus with a distinct "master" (the most frequent) sequence (5,10). To define cleavage by RNase P as a general property of HCV, four viral sequences obtained from different patients, together with S I sequence (referred to as wild type here), were compared for RNase P cleavage accessibility (Fig. 6A) . We used transcripts from cloned HCV PCR fragments, representing the master sequence from infected patients' quasispecies, with mutations at the vicinity or exactly at the nucleotides adjacent to the scissile bond in the structural/non-structural junction. Cleavage was consistently observed in all sequences tested although with different efficiencies (Fig. 6B) .
HCV RNA competes with RNase P cleavage of pre-tRNA.
The concept of RNA mimicry has been defined for those cases where the structure of an RNA molecule has evolved to fit a binding site on a protein or a macromolecular complex which normally interacts with a different RNA (33) . The specific cleavage of HCV RNA by RNase P suggests that the viral RNA has structural similarities to tRNA. We wished to assess how much these HCV RNA structures resemble tRNA. In competition experiments reciprocal to those shown in figure 5 , we tested the ability of HCV RNA transcripts S I and S III (0.9 nM to 180 nM)
to compete for RNase P activity with the natural substrate pre-tRNA Tyr (1.8 nM). Figure 7 shows that by using an RNase P concentration capable of cleaving around 25% of the pretRNA Tyr in the reaction, the amount of pre-tRNA cleavage products decreased with increasing HCV RNA concentration. The amount of HCV RNAs required for half inhibition were between 4 to 6 fold molar excess and were similar for both S I and S III . In contrast, similar amounts of an unrelated RNA of 400nt length corresponding to hepatitis B virus surface antigen mRNA (nt 1400 to nt 1800 of HBV adr subtype) (34) which is not cleaved by RNase P, had no observable effect on RNase P activity on pre-tRNA (data not shown). The fact that the HCV RNA is a competitive inhibitor of pre-tRNA cleavage within one order of magnitude range evidences molecular mimicry between the HCV RNA motifs at the cleavage sites and those in pre-tRNA.
Furthermore, the inhibition of pre-tRNA cleavage provides strong evidence that the interaction of HCV RNA is with RNase P and not with RNase MRP, in agreement with our previous conclusion that RNase P is responsible for HCV RNA cleavage.
The results in Figures 2 and 3 , which were first completed using RNAs produced and cleaved in the Barcelona lab, have also been repeated in the New York lab. These experiments were repeated using two different preparation of human RNase P (from Dr. Sidney Altman) and the same results were reproduced.
DISCUSSION
We have defined a new specific interaction in vitro between HCV RNA and a host component, RNase P; and we have confirmed that HCV RNA transcripts act as competitive inhibitors of pre-tRNA tyr processing. This represents evidence for a similarity in structure and/or function between both accessible motifs in HCV RNA and tRNA molecules.
RNase P specifically cleaves pre-tRNA in all organisms to produce mature 5' ends. There have been questions raised about the universal significance of RNase P cleavage in non-tRNA molecules, especially concerning yeast RNase P. Chamberlain et al. (35) have suggested that yeast RNase P can sometimes cleave 5.8S rRNA at sites which lack properties normally associated with canonical tRNA. Given the uncertain evolutionary history of this rRNA species, however, it is hard to prove or disprove the acquisition of internal tRNA-like domains, which are in fact present in analogous prokaryotic spacer regions of rRNA precursors. It is also the case that RNase P cleavage has reliably identified a number of authenticated tRNA-like domains in non-tRNA molecules, including bacterial SRP and tmRNAs and various plant viral RNA genomes (36) (37) (38) (39) (40) . Given that our two HCV domains undergo RNase P cleavage with the same efficiency as pre-tRNA, we believe that such recognition by RNase P is an indication for the presence of two possible tRNAlike structures in the HCV genome.
The ability to mimic tRNA as we observe here in HCV RNA was first discovered 30 years ago at the 3' end of the turnip yellow mosaic virus because its ability to undergo covalent linkage with amino acids catalyzed by aminoacyl tRNA synthetase (41) . Subsequently, this and other plant viral RNAs were seen to be accessible to a battery of factors involved in other tRNArelated activities (including accessibility of bacterial RNase P) (37, 41, 42) . Nevertheless, in vivo functional mimicry was not complete since viral RNAs were not amino acid donors for protein synthesis but rather participated in virus replication.
This proposed idea is further supported by the presence of a pseudoknot near the HCV IRES(43) cleavage site (a common element in tRNA-like structures including that which is known to interact with E.coli RNase P in the case of the tRNA-like motifs of plant viral RNAs)(42) (Fig. 8) .
Such a structure might contribute to the recruitment of the translational machinery in the absence of a 5' terminal cap. A recent study by J.R. Lytle et al. (44) , confirms that this pseudoknot domain of the HCV IRES is among those protected from extensive pancreatic RNase A digestion by initiating 80S ribosomes.
During protein elongation, this RNA structure might also help a ribosomal frameshift which has been described to happen within cleavage boundaries and that generates a new antigen in HCV infected patients (45, 46) .
Concerning the internal cleavage site, the predicted secondary structure formed by the RNA sequence flanking the cleavage site (the cleavage is 5' to a G residue (G 2861 ) and is followed by two helices totaling 13 bases connected through a bulge (program: RNA structure 3.5) is in agreement with the characteristic features of the minimal model substrate for human RNase P (47) (Fig. 8) . In particular, cleavage determinants are confined to the tRNA domain that contains the acceptor stem, the T stem and loop, and the junction between them (47), a recognition feature also shared by the E.coli elongation factor EFTu (33) . Also, the internal HCV RNase P cleavage site resides in a highly structured domain of the viral RNA (data not shown), which might be also compatible with a tRNA structure. Nevertheless, there is no readily obvious functional explanation for such a structure at this site.
The presence of HCV RNA in the nucleus (where most RNase P is found) has not been demonstrated (48) , and no evidence of subgenomic HCV RNAs has been reported (49), arguing against an active role of RNase P cleavage in HCV biology. Whatever the role of the RNase P-sensitive structures, their importance for virus viability is apparent, despite the notorious heterogeneity and dynamics of change in HCV quasispecies within the infected patient. A cleavage site at residue A2860, present in the master sequences from individual patients (differing at or near the position of cleavage), should be interpreted in a context where variants arise continuously, and are repeatedly subjected to competition pressures. Thus the relative success of a mutant is the result of its ability to replicate. This strongly supports that (i) the RNA structure that confers accessibility to RNase P is not affected by mutations which become fixed within the cleavage boundaries during error-prone replication; (ii) there is a continuous selective advantage for the sequences within the quasispecies carrying the RNase P-accessible structure. Moreover, conservation of RNase P-cleavable structures in the genomes of different patients implies that this structure is even conserved during genetic bottlenecking of HCV quasispecies during hostto-host transmission, in spite of the fact that this area is one of the most variable regions of the HCV genome at the nucleotide sequence level (6) . Altogether, this makes RNase P cleavability an inherent property of HCV.
Higher-order structures of RNA play functional roles, and the mutations that alter such higher-order structures must be subjected to negative selection. Such a strong tendency to maintain RNase P-sensitive structures within the viral genome might be important in the development of therapeutic strategies against the virus because they can represent highly susceptible targets for E. coli RNase P M1 RNA (22, 23) .
The next phase of this work will involve investigation of the minimum requirements for Correspondence and requests for material should be addressed to J. Gómez. 
